Stanford Cancer Institute
Head and Neck

Relapsed or Metastatic

Treatment

Squamous Cell Carcinoma of Head and Neck

No Prior Chemotherapy

Advanced Disease

Prior Chemotherapy

Squamous Cell Carcinoma of Head and Neck

ENT0055
Phase III Nivolumab in Combo w/ Ipilimumab vs Cetuximab +Cisplatin/ Carboplatin +Fluorouracil in SCCHN
Pi: Colevas Bristol Myers-Squibb

ENT0052
Phase I/II Anti-CD27 Antibody(Varilimumab) + Anti-PD-1(Nivolumab) in Advanced Refractory Solid Tumors
Pi: Sikic Celldex Therapeutics

ENT0062
Phase III Gemcitabine & Carboplatin +/- Virusspecific Autologous CTL in Nasopharyngeal Carcinoma
Pi: Colevas Innate Pharm SA

ENT0061
Pilot PD-1 Inhibition in Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Pi: Colevas Stanford

Ameloblastoma

ENT0043
A Pilot Study of Dabrafenib for Patients with BRAF-Mutated Ameloblastoma
Pi: Colevas Stanford

ENT0050
Ph 1 Panitumumab-IRDye800 Optical Imaging Agent to Detect Head and Neck Cancer During Surgery
Pi: Rosenthal Stanford

ENT0049
Ph 1 Cetuximab-IRDye800 as an Optical Imaging Agent to Detect Cancer During Surgical Procedures
Pi: Rosenthal Stanford

ENT0051
No Prior Chemotherapy

Diagnostic

Squamous Cell Carcinoma of Head and Neck

Supportive Care

Correlative

Nasopharyngeal Carcinoma

ENT0056
Phase III Nivolumab in Combo w/ Ipilimumab vs Cetuximab +Cisplatin/ Carboplatin +Fluorouracil in SCCHN
Pi: Colevas Bristol Myers-Squibb

ENT0132
Phase I/II Anti-CD27 Antibody(Varilimumab) + Anti-PD-1(Nivolumab) in Advanced Refractory Solid Tumors
Pi: Sikic Celldex Therapeutics

KEY

- - Optional Path

- - Link

Pending

Open for Enrollment

Observational Study

Extension Study

Enrollment on Hold

Immunotherapy

Please mark up a copy using black ink and fax changes to 725-9204